Review Article
Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review
Table 1
Incidence and severity of hypersensitivity to platinum agents.
| | Drug | Overall incidence % | Characteristics/Severity |
| | Cisplatin | 5–20 | Occurs within minutes of infusion start | | Mostly between 4th–8th course | | Increases with concomitant radiation |
| | Carboplatin | 1–44 | Occurs within minutes or days from infusion | | less than 1% during cycles 1–5 | | 6.5% in cycle 6 | | 27% in cycle 7 or more | | 44% in 3rd-line retreatment | | Half of all reactions observed are moderate to severe |
| | Oxaliplatin | 10–18.9 | Occurs within minutes/hours from infusion | | Mostly after 6th course | | Grade 3-4 in only 1.6% | | Severe anaphylaxis mostly in case reports |
|
|
